|
|
|
| Effect of Shenqi Fuzheng Injection on Cardiac Toxicity Induced by Targeted Therapy for Her2-Positive Breast Cancer |
| WANG Li, DUAN Wang-wang, WANG Song |
| Baota District Center for Disease Control and Prevention, Yan'an City, Shaanxi Province, pharmaceutical preparation section, Yan'an, Shaanxi Province 716000 |
|
|
|
|
Abstract 【Objective】To investigate the effect of Shenqi Fuzheng injection on prevention and treatment of cardiac toxicity induced by human epidermal growth factor receptor-2 (Her2) -positive breast cancer. 【Methods】A total of 80 cases of Her2-positive, estrogen and progesterone-negative breast cancer (ERBB2 + breast cancer) treated in our hospital were selected, and the patients were divided into two groups according to the random number table method. There were 40 cases in the observation group and 40 cases in the control group. Patients in the control group received trastuzumab combined with chemotherapy for injection, while patients in the observation group received Shenqi Fuzheng injection on the basis of the control group treatment. The Karnofsky score (KPS), myocardial enzymes [troponin I (cTnI) and creatine kinase isoenzyme (CK-MB)], left ventricular ejection fraction (LVEF) before and after chemotherapy, and the degree of side effects, ECG changes, and recurrence and metastasis were observed. 【Results】There were no significant differences in KPS, syndrome score, quality of life score, myocardial enzymes, and LVEF between the two groups before chemotherapy (all P> 0.05). At the end of chemotherapy, KPS, various quality of life scores, and LVEF in the observation group were higher than those of the control group and the syndrome score, cTnI, and CK-MB were lower than those of the control group; the differences were statistically significant (P<0.05). The proportion of grade 0 cardiac toxicity in the observation group (32 cases, 80.0%) was higher than that in the control group (21 cases, 52.5%, P<0.05). After chemotherapy, the rate of ECG change in the observation group (7.50%) was lower than that in the control group (27.50%) (P<0.05). There were no significant differences in the recurrence rate (12.50% vs. 12.50%), metastasis rate (5.00% vs. 7.50%), and mortality (10.00% vs. 7.50%) between the two groups after 2 years of follow-up (P>0.05). 【Conclusion】Shenqi Fuzheng Injection can reduce cardiac toxicity caused by targeted therapy of Her2-positive breast cancer and improve quality of life.
|
|
Received: 01 April 2021
|
|
|
|
|
|
[1] AKOZ G, DINIZ G, EKMEKCI S, et al. Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer[J].Indian J Pathol Microbiol,2018,61(3):323-329.
[2] 王春晖,李静,吴薇, 等.曲妥珠单抗治疗HER2阳性肿瘤患者的心脏安全性评价[J].药物不良反应杂志,2019,21(4):265-272.
[3] 隆耀莹,徐柳月,唐晓琼, 等.参芪扶正注射液防治蒽环类药物心脏毒性的Meta分析[J].检验医学与临床,2019,16(11):1550-1554.
[4] 李宏,何萌,黎亮, 等.参芪扶正注射液联合地西他滨对急性髓系白血病患者血清HGF、VEGF与LDH水平的影响[J].现代生物医学进展,2018,18(6):1085-1088.
[5] 中国华人民共和国卫生部. 中国常见恶性肿瘤诊治规范[M].北京医科大学、中国协和医科大学联合出版社, 1991.
[6] KHANJANI F, SAJEDI R H, HASNNIA S. Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay[J].Anal Bioanal Chem,2018,410(30):7827-7835.
[7] ZHANG H, CHEN T, SHAN L. ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis[J].Pharm Biol,2019,57(1):612-624.
[8] 陈晓珩,何蓓,李会龙, 等.基于RNAi技术研究参芪扶正注射液联合IFN-α对肝癌细胞增殖能力的影响[J].中国现代普通外科进展,2018,21(5):337-341.
[9] 吴惠珍,邱学佳,董占军, 等.参芪扶正注射液联合常规化疗对晚期非小细胞肺癌患者免疫功能影响的Meta分析[J].中国药房,2019,30(22):3143-3149.
[10] 吴佳欢,谢保城,王清辉, 等.参芪扶正注射液联合化疗治疗乳腺癌患者的系统评价[J].中国中药杂志,2019,44(3):589-596. |
|
|
|
2021, Vol. 38 
